BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 15246624)

  • 1. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques.
    Klinman DM; Xie H; Little SF; Currie D; Ivins BE
    Vaccine; 2004 Jul; 22(21-22):2881-6. PubMed ID: 15246624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine.
    Klinman DM
    Expert Rev Vaccines; 2006 Jun; 5(3):365-9. PubMed ID: 16827620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine.
    Klinman DM; Xie H; Ivins BE
    Ann N Y Acad Sci; 2006 Oct; 1082():137-50. PubMed ID: 17145935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.
    Xie H; Gursel I; Ivins BE; Singh M; O'Hagan DT; Ulmer JB; Klinman DM
    Infect Immun; 2005 Feb; 73(2):828-33. PubMed ID: 15664922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109.
    Gu M; Hine PM; James Jackson W; Giri L; Nabors GS
    Vaccine; 2007 Jan; 25(3):526-34. PubMed ID: 16973247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.
    Parreiras PM; Sirota LA; Wagner LD; Menzies SL; Arciniega JL
    Vaccine; 2009 Jul; 27(33):4537-42. PubMed ID: 19501205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
    Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
    Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P; Sukumaran B; Saxena S; Madhubala R
    Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine.
    Klinman DM; Yamamoto M; Tross D; Tomaru K
    Expert Opin Biol Ther; 2009 Dec; 9(12):1477-86. PubMed ID: 19769541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques.
    Livingston BD; Little SF; Luxembourg A; Ellefsen B; Hannaman D
    Vaccine; 2010 Jan; 28(4):1056-61. PubMed ID: 19896452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals.
    Hewetson JF; Little SF; Ivins BE; Johnson WM; Pittman PR; Brown JE; Norris SL; Nielsen CJ
    Vaccine; 2008 Aug; 26(33):4262-6. PubMed ID: 18586363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.
    Sloat BR; Cui Z
    J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
    Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
    Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain.
    Flick-Smith HC; Waters EL; Walker NJ; Miller J; Stagg AJ; Green M; Williamson ED
    Microb Pathog; 2005 Jan; 38(1):33-40. PubMed ID: 15652293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.
    Semenova VA; Schmidt DS; Taylor TH; Li H; Steward-Clark E; Soroka SD; Ballard MM; Quinn CP
    Vaccine; 2007 Feb; 25(10):1780-8. PubMed ID: 17229495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli.
    Sloat BR; Cui Z
    Vaccine; 2006 Sep; 24(40-41):6405-13. PubMed ID: 16828937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.
    Berthold I; Pombo ML; Wagner L; Arciniega JL
    Vaccine; 2005 Mar; 23(16):1993-9. PubMed ID: 15734073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.
    Quinn CP; Sabourin CL; Niemuth NA; Li H; Semenova VA; Rudge TL; Mayfield HJ; Schiffer J; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Brys AM; Hunt RE; Levesque D; Estep JE; Barnewall RE; Robinson DM; Plikaytis BD; Marano N;
    Clin Vaccine Immunol; 2012 Nov; 19(11):1730-45. PubMed ID: 22933399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine.
    Lininger LA; Cullum ME; Lyles MB; Bienek DR
    Vaccine; 2007 Feb; 25(9):1619-25. PubMed ID: 17150286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization.
    Li H; Soroka SD; Taylor TH; Stamey KL; Stinson KW; Freeman AE; Abramson DR; Desai R; Cronin LX; Oxford JW; Caba J; Pleatman C; Pathak S; Schmidt DS; Semenova VA; Martin SK; Wilkins PP; Quinn CP
    J Immunol Methods; 2008 Apr; 333(1-2):89-106. PubMed ID: 18304568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.